EGFR-IN-60, identified by its CAS number 2699877-43-3, is a small molecule inhibitor specifically targeting the epidermal growth factor receptor (EGFR), which plays a crucial role in cell signaling pathways that regulate cell proliferation and survival. This compound is part of a broader class of targeted therapies used in cancer treatment, particularly for tumors that exhibit overexpression or mutations in the EGFR gene. Characteristically, EGFR-IN-60 is designed to interfere with the receptor's activity, thereby inhibiting tumor growth and promoting apoptosis in cancer cells. The compound's efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, bioavailability, and potential side effects. As a research chemical, it may also be utilized in various biochemical assays to further understand EGFR-related signaling pathways and the development of resistance mechanisms in cancer therapy. Overall, EGFR-IN-60 represents a promising avenue in the ongoing effort to develop more effective and targeted cancer treatments.

EGFR-IN-60

2699877-43-3: EGFR-IN-60, identified by its CAS number 2699877-43-3, is a small molecule inhibitor specifically targeting the epidermal growth factor receptor (EGFR), which plays a crucial role in cell signaling pathways that regulate cell proliferation and survival. This compound is part of a broader class of targeted therapies used in cancer treatment, particularly for tumors that exhibit overexpression or mutations in the EGFR gene. Characteristically, EGFR-IN-60 is designed to interfere with the receptor's activity, thereby inhibiting tumor growth and promoting apoptosis in cancer cells. The compound's efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, bioavailability, and potential side effects. As a research chemical, it may also be utilized in various biochemical assays to further understand EGFR-related signaling pathways and the development of resistance mechanisms in cancer therapy. Overall, EGFR-IN-60 represents a promising avenue in the ongoing effort to develop more effective and targeted cancer treatments.

<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>

CAS 2699877-43-3

EGFR-IN-60

EGFR-IN-60

Ref: TM-T63769